Company Analysis Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
1. Summary
Advantages
- Price (0 Β₯) is less than fair price (1.64 Β₯)
- Dividends (3.06%) are higher than the sector average (0.3975%).
- The stock's return over the last year (0%) is higher than the sector average (-25.72%).
- The company's current efficiency (ROE=10.9%) is higher than the sector average (ROE=6.65%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 0% | 1.2% | 2.1% |
| 90 days | 0% | 12.2% | 17.8% |
| 1 year | 0% | -25.7% | 23.4% |
1349 vs Sector: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. has outperformed the "Healthcare" sector by 25.72% over the past year.
1349 vs Market: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. has significantly underperformed the market by -23.39% over the past year.
Stable price: 1349 is not significantly more volatile than the rest of the market on "Shanghai Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 1349 with weekly volatility of 0% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (0 Β₯) is lower than the fair price (1.64 Β₯).
4.2. P/E
P/E vs Sector: The company's P/E (10.26) is lower than that of the sector as a whole (41.44).
P/E vs Market: The company's P/E (10.26) is lower than that of the market as a whole (64.64).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (1.11) is lower than that of the sector as a whole (3.68).
P/BV vs Market: The company's P/BV (1.11) is lower than that of the market as a whole (3.08).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.93) is lower than that of the sector as a whole (20.2).
P/S vs Market: The company's P/S indicator (1.93) is lower than that of the market as a whole (6.41).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (20.56) is higher than that of the sector as a whole (16.62).
EV/Ebitda vs Market: The company's EV/Ebitda (20.56) is higher than that of the market as a whole (17.31).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by 0% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (0%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (9.32%).
5.4. ROE
ROE vs Sector: The company's ROE (10.9%) is higher than that of the sector as a whole (6.65%).
ROE vs Market: The company's ROE (10.9%) is higher than that of the market as a whole (8.24%).
5.5. ROA
ROA vs Sector: The company's ROA (5.94%) is higher than that of the sector as a whole (3.59%).
ROA vs Market: The company's ROA (5.94%) is higher than that of the market as a whole (4.08%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (0%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (0%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 3.06% is higher than the average for the sector '0.3975%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 3.06% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 3.06% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (54.83%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
